Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 4, 2026HemaSphereOpen Access

Idecabtagene vicleucel and endogenous T‐cell phenotypes linked to progression‐free survival in relapsed multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

BPBruno PaivaIMIrene ManriqueETEthan Thompson

Discussion

Loading...

Member takes

Overview

Randomized trial investigates T-cell characteristics and outcomes in relapsed multiple myeloma, suggesting implications for immunotherapy.

Key Points

  • The research aims to understand how T-cell characteristics relate to progression-free survival in patients with relapsed multiple myeloma treated with idecabtagene vicleucel.
  • Analyzed 258 bone marrow aspirates from 107 multiple myeloma patients in the KarMMa trial.
  • Investigated immune dynamics using multidimensional and computational flow cytometry.
  • Identified associations between T-cell phenotypes and progression-free survival before and after CAR-T infusion.
  • Longer progression-free survival was associated with higher pre-treatment percentages of PD1 + cytotoxic T cells and ICOS − TIGIT + Tregs.
  • After CAR-T infusion, >1% CAR-T cells and a CD4/CD8 CAR-T-cell ratio >0.09 were linked to better progression-free survival.
  • Lower percentages of ICOS + TIGIT − Tregs showed the strongest correlation with extended progression-free survival.

Cite This Study

Paiva et al. (2026) studied this question.

synapsesocial.com/papers/6a48a60a89561a0c2d78e547https://doi.org/10.1002/hem3.70423
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies2025
  2. 2Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation2025 · 1 citations
  3. 3Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM2025
  4. 4Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)2025
  5. 5Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma2025 · 1 citations